BLA 103764 · Novartis
Simulect
Basiliximab · Single-Use · Interleukin-2 Receptor Blocking Antibody
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Sep 15, 2005 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
May 12, 1998
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
150
38 Phase 3, 6 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Immunology and inflammation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Basiliximab" as an intervention, any sponsor and status, largest first.
- Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01950819 · 2,037 participants · Start Dec 3, 2013 · Primary completion Feb 1, 2017
Drug: Induction therapy; Corticosteroids and 2 more · For: End Stage Renal Disease (ESRD); Chronic Kidney Disease (CKD); Hemodialysis and 2 more
Sites: Birmingham, Alabama; Loma Linda, California; Los Angeles, California · 184 sites in all
- A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney RejectionPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00717470 · 1,252 participants · Start May 14, 2008 · Primary completion Mar 2, 2010
Drug: Prograf®; Advagraf® and 3 more · For: Kidney Transplantation
Sites: Buenos Aires, Argentina; Córdoba, Argentina; Innsbruck, Austria · 110 sites in all
- A Study Looking at Diabetes in Kidney Transplant Recipients Receiving Immunosuppressive Regimen With or Without SteroidsPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT01304836 · 1,166 participants · Start Jan 22, 2011 · Primary completion May 22, 2013
Drug: Advagraf; Mycophenolate Mofetil and 2 more · For: Kidney Transplantation
Sites: Perth, Australia; Sydney, Australia; Brussels, Belgium · 100 sites in all
- Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver TransplantationPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT01011205 · 893 participants · Start Sep 30, 2009 · Primary completion Jan 4, 2013
Drug: Advagraf; Mycophenolate Mofetil and 2 more · For: Liver Transplantation
Sites: Buenos Aires, Argentina; Innsbruck, Austria; Minsk, Belarus · 72 sites in all
- Campath, Calcineurin Inhibitor Reduction and Chronic Allograft NephropathyPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT01120028 · 852 participants · Start Sep 2010 · Primary completion Feb 2014
Drug: Alemtuzumab; Basiliximab and 2 more · For: Kidney Transplantation
Sites: Oxford, United Kingdom; Birmingham, United Kingdom; Cambridge, United Kingdom · 20 sites in all
- Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant RecipientsPivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00251004 · 833 participants · Start Oct 2005 · Primary completion Aug 2009
Drug: Everolimus; Mycophenolic Acid (MPA) and 3 more · For: Kidney Transplantation; Graft Rejection
Sites: East Hanover, New Jersey
- Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose RegimenPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00514514 · 802 participants · Start Jul 2007 · Primary completion Jun 2015
Drug: Everolimus; Myfortic and 2 more · For: Kidney Transplantation
Sites: Aachen, Germany; Berlin, Germany; Cologne, Germany · 18 sites in all
- 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant PatientsPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01843348 · 612 participants · Start Dec 27, 2012 · Primary completion Mar 23, 2016
Drug: Everolimus; Tacrolimus and 5 more · For: Kidney Transplantation; Renal Transplantation
Sites: Poitiers, France; Bordeaux, France; Brest, France · 27 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Simulect (Basiliximab) · HCPCS J0480
2024 spending
$1.8M
Beneficiaries
207
396 claims
Per beneficiary
$8,592
2024 ASP limit $4,533.31 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,271,345 |
| 2021 | $1,791,468 |
| 2022 | $2,208,028 |
| 2023 | $2,033,681 |
| 2024 | $1,778,496 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis.
Rindi LV, Zaçe D, Braccialarghe N, et al. · Drug Saf 2024 · Systematic Review, Meta-Analysis
- Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials.
Sawitzki B, Harden PN, Reinke P, et al. · Lancet 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Cost-minimization study comparing Simulect vs. Thymoglobulin in renal transplant induction.
Lilliu H, Brun-Strang C, Le Pen C, et al. · Clin Transplant 2004 · Clinical Trial, Comparative Study
- Simulect induction facilitates Neoral-based steroid-free immunosuppression in primary kidney transplant recipients.
Kung SC, Parikh M, Fyfe B, et al. · Transplant Proc 2004 · Clinical Trial, Comparative Study
- Steroid-free liver transplantation in children.
Reding R, Gras J, Sokal E, et al. · Lancet 2003 · Clinical Trial, Comparative Study
- Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphoma.
Zain J, Tsai NC, Palmer J, et al. · Blood Adv 2024 · Clinical Trial, Phase I, Research Support, N.I.H., Extramural
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.